TY - JOUR
T1 - Double-edged sword
T2 - Impact of fecal microbiome transplants on the gut resistome
AU - Hallowell, Haley Anne
AU - Gao, Anne Lulu
AU - Suez, Jotham
N1 - Funding Information:
We thank the members of the Suez lab for fruitful discussions. A.L.G. is supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE2139757. J.S. is the inaugural Feinstone Assistant Professor in the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. Research in the Suez lab is supported by an NIH Director's Early Independence Award DP5-OD029603 and the Johns Hopkins Bloomberg School of Public Health. The figure in this manuscript was created with Biorender.com.
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Purpose of reviewFecal microbiome transplants (FMT) show promise in treating various diseases, such as Clostridioides difficile infections. FMT have also demonstrated the capacity to modulate the collection of antibiotic resistance genes (ARGs), termed the resistome, within the gut. The purpose of this review was to critically evaluate the literature regarding the interaction between FMT and the gut resistome and determine whether FMT could be used specifically to reduce ARG carriage in the gut.Recent findingsSeveral studies have demonstrated a decrease in ARG carriage post-FMT administration in various disease states, including recurrent C. difficile infection and after antibiotic usage. However, other studies have reported an expansion of the resistome following FMT. Most studies contained small patient cohorts regardless of the outcome and showed heterogeneity in responses.SummaryResearch on resistome modulation by FMT is preliminary, and human studies currently lack consensus regarding benefits and risks. From a safety perspective, screening donor samples for ARGs in addition to antibiotic-resistant organisms may be advisable. Additional studies on the mechanisms underlying heterogeneity between studies and individuals are required before FMT is considered an efficient approach for resistome amelioration.
AB - Purpose of reviewFecal microbiome transplants (FMT) show promise in treating various diseases, such as Clostridioides difficile infections. FMT have also demonstrated the capacity to modulate the collection of antibiotic resistance genes (ARGs), termed the resistome, within the gut. The purpose of this review was to critically evaluate the literature regarding the interaction between FMT and the gut resistome and determine whether FMT could be used specifically to reduce ARG carriage in the gut.Recent findingsSeveral studies have demonstrated a decrease in ARG carriage post-FMT administration in various disease states, including recurrent C. difficile infection and after antibiotic usage. However, other studies have reported an expansion of the resistome following FMT. Most studies contained small patient cohorts regardless of the outcome and showed heterogeneity in responses.SummaryResearch on resistome modulation by FMT is preliminary, and human studies currently lack consensus regarding benefits and risks. From a safety perspective, screening donor samples for ARGs in addition to antibiotic-resistant organisms may be advisable. Additional studies on the mechanisms underlying heterogeneity between studies and individuals are required before FMT is considered an efficient approach for resistome amelioration.
KW - antibiotic resistance genes
KW - antibiotics
KW - fecal microbiome transplant
KW - microbiome
KW - resistome
UR - http://www.scopus.com/inward/record.url?scp=85143806150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143806150&partnerID=8YFLogxK
U2 - 10.1097/MOG.0000000000000894
DO - 10.1097/MOG.0000000000000894
M3 - Review article
C2 - 36504032
AN - SCOPUS:85143806150
SN - 0267-1379
VL - 39
SP - 16
EP - 22
JO - Current opinion in gastroenterology
JF - Current opinion in gastroenterology
IS - 1
ER -